

Olivier Micheau

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1676859/olivier-micheau-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96
papers

9,140
citations

43
h-index

95
g-index

113
ext. papers

10,033
ext. citations

7.5
avg, IF

6
L-index

#	Paper	IF	Citations
96	The multifaceted role of TRAIL signaling in cancer and immunity. <i>FEBS Journal</i> , 2021 , 288, 5530-5554	5.7	8
95	Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy. <i>Cancer Immunology Research</i> , 2021 , 9, 568-582	12.5	9
94	Grafting TRAIL through Either Amino or Carboxylic Groups onto Maghemite Nanoparticles: Influence on Pro-Apoptotic Efficiency. <i>Nanomaterials</i> , 2021 , 11,	5.4	2
93	Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. <i>Cancer Letters</i> , 2020 , 472, 29-39	9.9	7
92	Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP. <i>Cells</i> , 2020 , 9,	7.9	5
91	Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy. <i>Cancers</i> , 2019 , 11,	6.6	19
90	Coupling tumor necrosis factor-related apoptosis-inducing ligand to iron oxide nanoparticles increases its apoptotic activity on HCT116 and HepG2 malignant cells: effect of magnetic core size. <i>Journal of Interdisciplinary Nanomedicine</i> , 2019 , 4, 34-50	4	6
89	Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization. <i>Cell Death and Disease</i> , 2019 , 10, 101	9.8	3
88	The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death. <i>Cell Death and Differentiation</i> , 2019 , 26, 443-454	12.7	18
87	TRAIL acts synergistically with iron oxide nanocluster-mediated magneto- and photothermia. <i>Theranostics</i> , 2019 , 9, 5924-5936	12.1	8
86	Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	40
85	Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes. <i>Oncotarget</i> , 2018 , 9, 15566-15578	3.3	6
84	Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis. <i>Cell Death and Disease</i> , 2018 , 9, 874	9.8	19
83	Immunoprecipitation of Death Inducing Signaling Complex by Caspase-8. <i>Methods in Molecular Biology</i> , 2017 , 1557, 19-31	1.4	3
82	N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death. <i>Cell Death and Differentiation</i> , 2017 , 24, 500-510	12.7	59
81	FLIP 2017 , 881-891		
80	TRAIL-NP hybrids for cancer therapy: a review. <i>Nanoscale</i> , 2017 , 9, 5755-5768	7.7	29

79	Posttranslational Modifications and Death Receptor Signalling. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017 , 247-290	0.3	
78	TRAIL, Fas Ligand, TNF and TLR3 in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017 ,	0.3	2
77	Marine actinomycete crude extracts with potent TRAIL-resistance overcoming activity against breast cancer cells. <i>Oncology Reports</i> , 2017 , 37, 3635-3642	3.5	10
76	Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy. <i>Antibodies</i> , 2017 , 6,	7	34
75	TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress. <i>Oncotarget</i> , 2017 , 8, 9974-9985	3.3	53
74	CC5 and CC8, two homologous disintegrins from <i>Cerastes cerastes</i> venom, inhibit in vitro and ex vivo angiogenesis. <i>International Journal of Biological Macromolecules</i> , 2016 , 86, 670-80	7.9	10
73	Enhanced DR5 binding capacity of nanovectorized TRAIL compared to its cytotoxic version by affinity chromatography and molecular docking studies. <i>Journal of Molecular Recognition</i> , 2016 , 29, 406-414	2.6	12
72	The mycotoxin zearalenone enhances cell proliferation, colony formation and promotes cell migration in the human colon carcinoma cell line HCT116. <i>Toxicology Letters</i> , 2016 , 254, 1-7	4.4	30
71	Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing. <i>Nano Letters</i> , 2015 , 15, 891-5	11.5	54
70	Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility. <i>Oncogene</i> , 2015 , 34, 996-1005	9.2	59
69	Sphingolipids modulate the epithelial-mesenchymal transition in cancer. <i>Cell Death Discovery</i> , 2015 , 1, 15001	6.9	12
68	Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). <i>Marine Drugs</i> , 2015 , 13, 6884-909	6	18
67	Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells. <i>PLoS ONE</i> , 2015 , 10, e0126526	3.7	7
66	Nanovector formation by functionalization of TRAIL ligand on single-walled carbon nanotube: Experimental and theoretical evidences. <i>Chemical Physics Letters</i> , 2015 , 633, 273-281	2.5	4
65	Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion. <i>Cell Death and Disease</i> , 2015 , 6, e1633	9.8	33
64	FLIP 2015 , 1-11		
63	Chemotherapy with ceramide in TNBC. <i>Oncoscience</i> , 2015 , 2, 817-8	0.8	1
62	Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells. <i>Cell Death and Disease</i> , 2014 , 5, e1016	9.8	18

61	TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013 , 18, 324-36	5.4	22
60	Targeting c-FLIP in cancer. <i>Cancer Letters</i> , 2013 , 332, 141-50	9.9	101
59	Death receptors as targets in cancer. <i>British Journal of Pharmacology</i> , 2013 , 169, 1723-44	8.6	135
58	Dual Role of TLR3 in Inflammation and Cancer Cell Apoptosis 2013 ,		6
57	Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. <i>FASEB Journal</i> , 2013 , 27, 1549-60	0.9	77
56	Thiocolchicoside a semi-synthetic derivative of the Glory Lily: a new weapon to fight metastatic bone resorption?. <i>British Journal of Pharmacology</i> , 2012 , 165, 2124-6	8.6	5
55	Identification of a novel pro-apoptotic role of NF- κ B in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells. <i>Oncogene</i> , 2012 , 31, 1468-74	9.2	46
54	Small heat shock proteins and the cytoskeleton: an essential interplay for cell integrity?. <i>International Journal of Biochemistry and Cell Biology</i> , 2012 , 44, 1680-6	5.6	118
53	dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. <i>Cell Death and Differentiation</i> , 2012 , 19, 1482-94	12.7	122
52	Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. <i>Haematologica</i> , 2012 , 97, 38-46	6.6	70
51	Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. <i>Gastroenterology</i> , 2011 , 141, 663-73	13.3	22
50	TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. <i>PLoS ONE</i> , 2011 , 6, e19679	3.7	50
49	Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011 , 6, 311-23	2.6	52
48	Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. <i>Cell Death and Differentiation</i> , 2011 , 18, 700-11	12.7	69
47	Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. <i>Cancer Research</i> , 2011 , 71, 484-95	10.1	124
46	Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. <i>Journal of Immunology</i> , 2010 , 184, 1876-84	5.3	43
45	Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. <i>Cancer Research</i> , 2010 , 70, 1101-10	10.1	77
44	Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?. <i>Cellular and Molecular Life Sciences</i> , 2010 , 67, 3115-30	10.3	49

43	The heme oxygenase-1 and c-FLIP in acute myeloid leukemias: two non-redundant but mutually exclusive cellular safeguards protecting cells against TNF-induced cell death?. <i>Oncotarget</i> , 2010 , 1, 317-319	7
42	The heme oxygenase-1 and c-FLIP in acute myeloid leukemias: two non-redundant but mutually exclusive cellular safeguards protecting cells against TNF-induced cell death?. <i>Oncotarget</i> , 2010 , 1, 317-319	6
41	Distinct requirements for activation-induced cell surface expression of preformed Fas/CD95 ligand and cytolytic granule markers in T cells. <i>Cell Death and Differentiation</i> , 2009 , 16, 115-24	12.7 22
40	Molecular crosstalk between TRAIL and natural antioxidants in the treatment of cancer. <i>British Journal of Pharmacology</i> , 2009 , 157, 1186-8	8.6 20
39	Colony-stimulating factor-1-induced oscillations in phosphatidylinositol-3 kinase/AKT are required for caspase activation in monocytes undergoing differentiation into macrophages. <i>Blood</i> , 2009 , 114, 3633-41	2.2 44
38	A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. <i>Oncogene</i> , 2008 , 27, 6012-22	9.2 76
37	P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. <i>Oncogene</i> , 2008 , 27, 4161-71	9.2 31
36	CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. <i>Journal of Immunology</i> , 2008 , 181, 1001-11	5.3 67
35	Ectopic expression of the serine protease inhibitor PI9 modulates death receptor-mediated apoptosis. <i>Cell Death and Differentiation</i> , 2007 , 14, 1486-96	12.7 27
34	Deglycosylated bleomycin induces apoptosis in lymphoma cell via c-jun NH2-terminal kinase but not reactive oxygen species. <i>Biochemical Pharmacology</i> , 2007 , 74, 1445-55	6 8
33	Catalytically active Yersinia outer protein P induces cleavage of RIP and caspase-8 at the level of the DISC independently of death receptors in dendritic cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007 , 12, 1813-25	5.4 28
32	TRAIL induces receptor-interacting protein 1-dependent and caspase-dependent necrosis-like cell death under acidic extracellular conditions. <i>Cancer Research</i> , 2007 , 67, 218-26	10.1 52
31	Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation. <i>Blood</i> , 2007 , 109, 1442-50	2.2 104
30	TRAIL in cancer therapy: present and future challenges. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 1299-314	6.4 124
29	Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappaB-related survival pathway down-regulation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 316, 304-14	4.7 61
28	Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. <i>Molecular and Cellular Biology</i> , 2006 , 26, 7046-55	4.8 241
27	Differential mechanisms of conjunctival cell death induction by ultraviolet irradiation and benzalkonium chloride. <i>Investigative Ophthalmology and Visual Science</i> , 2006 , 47, 4221-30	35
26	E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short). <i>Cell Death and Differentiation</i> , 2006 , 13, 260-72	12.7 58

25	Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. <i>Oncogene</i> , 2004 , 23, 8979-86	9.2	161
24	Cellular FLICE-inhibitory protein: an attractive therapeutic target?. <i>Expert Opinion on Therapeutic Targets</i> , 2003 , 7, 559-73	6.4	78
23	LF 15-0195 immunosuppressive agent enhances activation-induced T-cell death by facilitating caspase-8 and caspase-10 activation at the DISC level. <i>Blood</i> , 2003 , 101, 194-201	2.2	13
22	Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. <i>Oncogene</i> , 2003 , 22, 1807-16	9.2	112
21	Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. <i>Cell</i> , 2003 , 114, 181-90	56.2	1937
20	Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. <i>Immunity</i> , 2003 , 18, 655-64	32.3	369
19	Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. <i>Journal of Biological Chemistry</i> , 2003 , 278, 16183-8	5.4	53
18	Overexpression of Helicard, a CARD-containing helicase cleaved during apoptosis, accelerates DNA degradation. <i>Current Biology</i> , 2002 , 12, 838-43	6.3	110
17	Overexpression of Helicard, a CARD-Containing Helicase Cleaved during Apoptosis, Accelerates DNA Degradation. <i>Current Biology</i> , 2002 , 12, 1633	6.3	2
16	The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. <i>Journal of Biological Chemistry</i> , 2002 , 277, 45162-71	5.4	363
15	NF-kappaB signals induce the expression of c-FLIP. <i>Molecular and Cellular Biology</i> , 2001 , 21, 5299-305	4.8	696
14	Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique C-terminal extension. <i>Journal of Biological Chemistry</i> , 2001 , 276, 19548-54	5.4	85
13	Equine herpesvirus protein E10 induces membrane recruitment and phosphorylation of its cellular homologue, bcl-10. <i>Journal of Cell Biology</i> , 2001 , 152, 1115-22	7.3	18
12	Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation. <i>FEBS Letters</i> , 2001 , 496, 121-7	3.8	165
11	Corrigendum to: Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF- κ B activation (FEBS 24842). <i>FEBS Letters</i> , 2001 , 505, 198-198	3.8	1
10	Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. <i>Nature Immunology</i> , 2000 , 1, 489-95	19.1	1387
9	FIST/HIPK3: a Fas/FADD-interacting serine/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-terminal kinase activation. <i>Journal of Experimental Medicine</i> , 2000 , 192, 1165-74	16.6	92
8	P27Kip1 overexpression inhibits the growth and doxorubicin sensitivity of HT29 human colon cancer cells in vivo. <i>Anticancer Research</i> , 2000 , 20, 849-52	2.3	4

7	Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. <i>Journal of Biological Chemistry</i> , 1999 , 274, 7987-92	5-4	246
6	STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 256, 603-7	3-4	56
5	Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. <i>Cell Death and Differentiation</i> , 1998 , 5, 480-7	12-7	83
4	Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. <i>International Journal of Cancer</i> , 1998 , 77, 796-802	7-5	30
3	Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 783-9	9-7	258
2	Cellular FLICE-inhibitory Protein: An Update 120-156		2
1	Cellular FLICE-inhibitory protein: an attractive therapeutic target?		0